Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Inclusion Criteria: * histologically and immunohistochemically confirmed status of the tumor process * мale or female, age ≥ 18 years * Karnofsky performance status ≥ 60 * signed informed consent and willingness/ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures Exclusion Criteria: * Grade 3 bleeding NCI CTCAE prior to study enrollment * cardiac arrhythmias ≥2 according to NCI CTCAE with a corrected QT interval (QTcF) on the screening ECG \>480 ms. * pregnancy or breastfeeding. All female subjects of reproductive potential must have a negative pregnancy test (serum) prior to enrollment. Male subjects must be surgically sterile or must consent to the use of effective contraception during therapy. * severe acute or chronic psychiatric condition or disorder with risk associated with participation in the study * congestive heart failure (CHF) class III or higher according to the New York Heart Association (NYHA) * subjects with arterial thrombotic events / venous thrombosis in the previous 12 months (axitinib has never been studied in this population)